Non-viral <i>ex vivo</i> genome-editing in mouse bona fide hematopoietic stem cells with CRISPR/Cas9.

导出 LinkOut

翻译打印收藏纠错

作者： Suvd,Byambaa ^[1] ; Hideki,Uosaki ^[1] ; Tsukasa,Ohmori ^[2] ; Hiromasa,Hara ^[1] ; Hitoshi,Endo ^[3] ; Osamu,Nureki ^[4] ; Yutaka,Hanazono ^[1]

作者单位： Division of Regenerative Medicine, Center for Molecular Medicine, Jichi Medical University, Tochigi 329-0498, Japan. ^[1] Division of Medical Biochemistry, Department of Biochemistry, School of Medicine, Jichi Medical University, Tochigi 329-0498, Japan. ^[2] Division of Functional Biochemistry, Department of Biochemistry, School of Medicine, Jichi Medical University, Tochigi 329-0498, Japan. ^[3] Department of Biological Sciences, Graduate School of Science, The University of Tokyo, Tokyo 113-0033, Japan. ^[4]

关键词 CRISPR/Cas9 X-linked severe combined immunodeficiency hematopoietic stem cells homology-independent targeted integration non-viral genome editing

DOI 10.1016/j.omtm.2021.01.001

PMID 33614821

发布时间 2021-02-23

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Molecular therapy. Methods & clinical development

2021年20卷

451-462页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Non-viral <i>ex vivo</i> genome-editing in mouse bona fide hematopoietic stem cells with CRISPR/Cas9.

Molecular therapy. Methods & clinical development

相似文献

Molecular therapy. Methods & clinical development

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Non-viral <i>ex vivo</i> genome-editing in mouse bona fide hematopoietic stem cells with CRISPR/Cas9.

Molecular therapy. Methods & clinical development

相似文献

Molecular therapy. Methods & clinical development

相关期刊

检索历史清除